RxDoctor Payments Data

Lisa Jackson

Nurse Practitioner · Anchorage, AKNPI 1770775827

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 44.7% of the total. Reporting peaked in 2022 at $190 and has fallen 84.7% since, to $29 in 2025.

$591in general payments, 2019–2025

Across 27 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$264
  • Novo Nordisk$103
  • Amgen$68
  • Sanofi Pasteur Inc.$52
  • Biohaven Pharmaceutical Holding Company Ltd.$35
  • Lilly USA, LLC$19
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$591 in reported general payments places this provider in the 80th percentile of 212 nurse practitioner providers in Alaska.

See all nurse practitioner providers in Alaska

Medicare billing

Part B allowed, 2024
$19,165
Medicare patients
63
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$63,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,515
EliquisApixaban15$11,249
Valsartan14$972
Atorvastatin Calcium43$410
Gabapentin15$387
Acebutolol Hcl12$368
Omega-3 Acid Ethyl Esters13$358
Lisinopril18$223
Metformin Hcl ErMetformin Hcl26$190
Rosuvastatin Calcium14$177
Amlodipine Besylate27$177
Losartan Potassium14$158
Famotidine14$105
Metformin Hcl13$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$63,25054 claims
GSKTrelegy Ellipta$16$13,51514 claims
PfizerEliquis$17$11,24915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 212 nurse practitioner providers in Alaska.

Other nurse practitioner in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →